Testing for HIV Integrase Inhibitor Resistance: 2024 and Beyond

HIV drug resistance (HIVDR) can emerge with use of antiretroviral (ARV) drugs for HIV treatment and prevention. The increasing prevalence of drug-resistant HIV strains poses a serious threat to the progress made over the past decades in combating the HIV epidemic and can be attributed to various factors, including incomplete adherence to ARV drug regimens, suboptimal drug availability, and transmission of drug-resistant HIV strains. The World Health Organization (WHO) estimates that approximately 10% of people initiating ARV treatment (ART) globally have drug-resistant HIV strains.

This webinar will bring forward the perspectives of key opinion leaders in the field of HIVDR to discuss the current state of drug resistance globally, use of HIV drug resistance testing for public health surveillance and clinical management of persons living with HIV (PLWH), and new challenges related to detection and monitoring of HIVDR. 

Learning Objectives:

• Learn about the increasing importance of population-level HIVDR surveillance testing and the potential of emerging resistance to integrase strand transfer inhibitors (INSTIs) to impact use of first-line dolutegravir-based ART regimens 
• Learn about use of HIV drug resistance testing for clinical management of PLWH in the era of INSTIs 
• Get updated on current and evolving methods for HIV drug resistance testing and the laboratory challenges posed by INSTIs